Vertex Pharmaceuticals

Quarterly Financials

Values in thousands 2024-12-31 2024-09-30 2024-06-30 2024-03-31
Revenue
$2,912,000
$2,771,900
$2,634,700
$2,687,200
Gross Profit
2,488,600
2,379,300
2,262,800
2,344,600
EBITDA
1,185,800
1,284,800
-3,327,300
1,343,000
EBIT
1,139,300
1,231,600
-3,381,300
1,289,500
Net Income
913,000
1,045,400
-3,593,600
1,099,600
Net Change In Cash
2,912,000
2,771,900
2,634,700
2,687,200
Free Cash Flow
492,000
1,489,800
-3,830,300
1,058,200
Cash
4,569,600
5,239,200
4,580,100
9,158,000
Basic Shares
260,500
261,000
258,100
261,100

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$11,020,100
$9,869,200
$8,930,700
$7,574,400
Gross Profit
9,489,600
8,607,000
7,850,400
6,670,200
EBITDA
486,300
4,605,200
4,435,500
2,917,500
EBIT
279,100
4,423,900
4,287,200
2,791,900
Net Income
-535,600
3,619,600
3,322,000
2,342,100
Net Change In Cash
11,020,100
9,869,200
8,930,700
7,574,400
Cost of Revenue
3,741,100
824,600
Free Cash Flow
-790,300
3,278,900
3,925,200
2,408,500
Cash
4,569,600
10,369,100
10,504,000
6,795,000
Basic Shares
257,899
260,500
259,100
259,899

Earnings Calls

Quarter EPS
2024-12-31
$3.98
2024-09-30
$4.38
2024-06-30
-$12.83
2024-03-31
$4.76